Machine Learning Techniques for the Diagnosis of Alzheimer’s Disease

AI for the prediction of early stages of Alzheimer's disease from neuroimaging biomarkers - A narrative review of a growing field

OBJECTIVES

The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD diagnosis, prognosis, and management.

METHODS

We conducted a narrative review of studies using AI techniques applied to neuroimaging data for early AD prediction. We examined single-modality studies using structural MRI and PET imaging, as well as multi-modality studies integrating multiple neuroimaging techniques and biomarkers. Furthermore, they reviewed longitudinal studies that model AD progression and identify individuals at risk of rapid decline.

RESULTS

Single-modality studies using structural MRI and PET imaging have demonstrated high accuracy in classifying AD and predicting progression from mild cognitive impairment (MCI) to AD. Multi-modality studies, integrating multiple neuroimaging techniques and biomarkers, have shown improved performance and robustness compared to single-modality approaches. Longitudinal studies have highlighted the value of AI in modeling AD progression and identifying individuals at risk of rapid decline. However, challenges remain in data standardization, model interpretability, generalizability, clinical integration, and ethical considerations.

CONCLUSION

AI techniques applied to neuroimaging data have the potential to improve early AD diagnosis, prognosis, and management. Addressing challenges related to data standardization, model interpretability, generalizability, clinical integration, and ethical considerations is crucial for realizing the full potential of AI in AD research and clinical practice. Collaborative efforts among researchers, clinicians, and regulatory agencies are needed to develop reliable, robust, and ethical AI tools that can benefit AD patients and society.

Comorbidity-based framework for Alzheimer's disease classification using graph neural networks

Alzheimer's disease (AD), the most prevalent form of dementia, requires early prediction for timely intervention. Current deep learning approaches, particularly those using traditional neural networks, face challenges such as handling high-dimensional data, interpreting complex relationships, and managing data bias. To address these limitations, we propose a framework utilizing graph neural networks (GNNs), which excel in modeling relationships within graph-structured data. Our study employs GNNs on data from the Alzheimer's Disease Neuroimaging Initiative for binary and multi-class classification across the three stages of AD: cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer's disease (AD). By incorporating comorbidity data derived from electronic health records, we achieved the most effective multi-classification results. Notably, the GNN model (Chebyshev Convolutional Neural Networks) demonstrated superior performance with a 0.98 accuracy in multi-class classification and 0.99, 0.93, and 0.94 in the AD/CN, AD/MCI, and CN/MCI binary tasks, respectively. The model's robustness was further validated using the Australian Imaging, Biomarker & Lifestyle dataset as an external validation set. This work contributes to the field by offering a robust, accurate, and cost-effective method for early AD prediction (CN vs. MCI), addressing key challenges in existing deep learning approaches.

Graph Embedded Intuitionistic Fuzzy Random Vector Functional Link Neural Network for Class Imbalance Learning

The domain of machine learning is confronted with a crucial research area known as class imbalance (CI) learning, which presents considerable hurdles in the precise classification of minority classes. This issue can result in biased models where the majority class takes precedence in the training process, leading to the underrepresentation of the minority class. The random vector functional link (RVFL) network is a widely used and effective learning model for classification due to its good generalization performance and efficiency. However, it suffers when dealing with imbalanced datasets. To overcome this limitation, we propose a novel graph-embedded intuitionistic fuzzy RVFL for CI learning (GE-IFRVFL-CIL) model incorporating a weighting mechanism to handle imbalanced datasets. The proposed GE-IFRVFL-CIL model offers a plethora of benefits: 1) leveraging graph embedding (GE) to preserve the inherent topological structure of the datasets; 2) employing intuitionistic fuzzy (IF) theory to handle uncertainty and imprecision in the data; and 3) the most important, it tackles CI learning. The amalgamation of a weighting scheme, GE, and IF sets leads to the superior performance of the proposed models on KEEL benchmark imbalanced datasets with and without Gaussian noise. Furthermore, we implemented the proposed GE-IFRVFL-CIL on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and achieved promising results, demonstrating the model's effectiveness in real-world applications. The proposed GE-IFRVFL-CIL model offers a promising solution to address the CI issue, mitigates the detrimental effect of noise and outliers, and preserves the inherent geometrical structures of the dataset.

Early Alzheimer's Disease Detection: A Review of Machine Learning Techniques for Forecasting Transition from Mild Cognitive Impairment

Alzheimer's disease is a weakening neurodegenerative condition with profound cognitive implications, making early and accurate detection crucial for effective treatment. In recent years, machine learning, particularly deep learning, has shown significant promise in detecting mild cognitive impairment to Alzheimer's disease conversion. This review synthesizes research on machine learning approaches for predicting conversion from mild cognitive impairment to Alzheimer's disease dementia using magnetic resonance imaging, positron emission tomography, and other biomarkers. Various techniques used in literature such as machine learning, deep learning, and transfer learning were examined in this study. Additionally, data modalities and feature extraction methods analyzed by different researchers are discussed. This review provides a comprehensive overview of the current state of research in Alzheimer's disease detection and highlights future research directions.

A systematic literature review on the significance of deep learning and machine learning in predicting Alzheimer's disease

BACKGROUND

Alzheimer's disease (AD) is the most prevalent cause of dementia, characterized by a steady decline in mental, behavioral, and social abilities and impairs a person's capacity for independent functioning. It is a fatal neurodegenerative disease primarily affecting older adults.

OBJECTIVES

The purpose of this literature review is to investigate various AD detection techniques, datasets, input modalities, algorithms, libraries, and performance evaluation metrics used to determine which model or strategy may provide superior performance.

METHOD

The initial search yielded 807 papers, but only 100 research articles were chosen after applying the inclusion-exclusion criteria. This SLR analyzed research items published between January 2019 and December 2022. The ACM, Elsevier, IEEE Xplore Digital Library, PubMed, Springer and Taylor & Francis were systematically searched. The current study considers articles that used Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), APOe4 genotype, Diffusion Tensor Imaging (DTI) and Cerebrospinal Fluid (CSF) biomarkers. The study was performed following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

CONCLUSION

According to the literature survey, most studies (n = 76) used the DL strategy. The datasets used by studies were primarily derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The majority of studies (n = 73) used single-modality neuroimaging data, while the remaining used multi-modal input data. In a multi-modality approach, the combination of MRI and PET scans is commonly preferred. Also, Regarding the algorithm used, Convolution Neural Network (CNN) showed the highest accuracy, 100 %, in classifying AD vs. CN subjects whereas the SVM was the most common ML algorithm, with a maximum accuracy of 99.82 %.

Performance Evaluation of Deep, Shallow and Ensemble Machine Learning Methods for the Automated Classification of Alzheimer's Disease

Artificial intelligence (AI)-based approaches are crucial in computer-aided diagnosis (CAD) for various medical applications. Their ability to quickly and accurately learn from complex data is remarkable. Deep learning (DL) models have shown promising results in accurately classifying Alzheimer's disease (AD) and its related cognitive states, Early Mild Cognitive Impairment (EMCI) and Late Mild Cognitive Impairment (LMCI), along with the healthy conditions known as Cognitively Normal (CN). This offers valuable insights into disease progression and diagnosis. However, certain traditional machine learning (ML) classifiers perform equally well or even better than DL models, requiring less training data. This is particularly valuable in CAD in situations with limited labeled datasets. In this paper, we propose an ensemble classifier based on ML models for magnetic resonance imaging (MRI) data, which achieved an impressive accuracy of 96.52%. This represents a 3-5% improvement over the best individual classifier. We evaluated popular ML classifiers for AD classification under both data-scarce and data-rich conditions using the Alzheimer's Disease Neuroimaging Initiative and Open Access Series of Imaging Studies datasets. By comparing the results to state-of-the-art CNN-centric DL algorithms, we gain insights into the strengths and weaknesses of each approach. This work will help users to select the most suitable algorithm for AD classification based on data availability.

Ensemble Deep Random Vector Functional Link Network Using Privileged Information for Alzheimer's Disease Diagnosis

Alzheimer's disease (AD) is a progressive brain disorder. Machine learning models have been proposed for the diagnosis of AD at early stage. Recently, deep learning architectures have received quite a lot attention. Most of the deep learning architectures suffer from the issues of local minima, slow convergence and sensitivity to learning rate. To overcome these issues, non-iterative learning based deep randomized models especially random vector functional link network (RVFL) with direct links have proven to be successful. However, deep RVFL and its ensemble models are trained only on normal samples. In this paper, deep RVFL and its ensembles are enabled to incorporate privileged information, as the standard RVFL model and its deep models are unable to use privileged information. To fill this gap, we have incorporated learning using privileged information (LUPI) in deep RVFL model, and propose deep RVFL with LUPI framework (dRVFL+). Privileged information is available while training the models. As RVFL is an unstable classifier, we propose ensemble deep RVFL+ with LUPI framework (edRVFL+) which exploits the LUPI as well as the diversity among the base leaners for better classification. Unlike traditional ensemble approach wherein multiple base learners are trained, the proposed edRVFL+ model optimises a single network and generates an ensemble via optimization at different levels of random projections of the data. Both dRVFL+ and edRVFL+ efficiently utilise the privileged information which results in better generalization performance. In LUPI framework, half of the available features are used as normal features and rest as the privileged features. However, we propose a novel approach for generating the privileged information. We utilise different activation functions while processing the normal and privileged information in the proposed deep architectures. To the best of our knowledge, this is first time that a separate privileged information is generated. The proposed dRVFL+ and edRVFL+ models are employed for the diagnosis of Alzheimer's disease. Experimental results demonstrate the superiority of the proposed dRVFL+ and edRVFL+ models over baseline models. Thus, the proposed edRVFL+ model can be utilised in clinical setting for the diagnosis of AD.

Graph Embedded Ensemble Deep Randomized Network for Diagnosis of Alzheimer's Disease

Randomized shallow/deep neural networks with closed form solution avoid the shortcomings that exist in the back propagation (BP) based trained neural networks. Ensemble deep random vector functional link (edRVFL) network utilize the strength of two growing fields, i.e., deep learning and ensemble learning. However, edRVFL model doesn't consider the geometrical relationship of the data while calculating the final output parameters corresponding to each layer considered as base model. In the literature, graph embedded frameworks have been successfully used to describe the geometrical relationship within data. In this paper, we propose an extended graph embedded RVFL (EGERVFL) model that, unlike standard RVFL, employs both intrinsic and penalty subspace learning (SL) criteria under the graph embedded framework in its optimization process to calculate the model's output parameters. The proposed shallow EGERVFL model has only single hidden layer and hence, has less representation learning. Therefore, we further develop an ensemble deep EGERVFL (edEGERVFL) model that can be considered a variant of edRVFL model. Unlike edRVFL, the proposed edEGERVFL model solves graph embedded based optimization problem in each layer and hence, has better generalization performance than edRVFL model. We evaluated the proposed approaches for the diagnosis of Alzheimer's disease and furthermore on UCI datasets. The experimental results demonstrate that the proposed models perform better than baseline models. The source code of the proposed models is available at https://github.com/mtanveer1/.

Identifying discriminative features of brain network for prediction of Alzheimer's disease using graph theory and machine learning

Alzheimer's disease (AD) is a challenging neurodegenerative condition, necessitating early diagnosis and intervention. This research leverages machine learning (ML) and graph theory metrics, derived from resting-state functional magnetic resonance imaging (rs-fMRI) data to predict AD. Using Southwest University Adult Lifespan Dataset (SALD, age 21-76 years) and the Open Access Series of Imaging Studies (OASIS, age 64-95 years) dataset, containing 112 participants, various ML models were developed for the purpose of AD prediction. The study identifies key features for a comprehensive understanding of brain network topology and functional connectivity in AD. Through a 5-fold cross-validation, all models demonstrate substantial predictive capabilities (accuracy in 82-92% range), with the support vector machine model standing out as the best having an accuracy of 92%. Present study suggests that top 13 regions, identified based on most important discriminating features, have lost significant connections with thalamus. The functional connection strengths were consistently declined for substantia nigra, pars reticulata, substantia nigra, pars compacta, and nucleus accumbens among AD subjects as compared to healthy adults and aging individuals. The present finding corroborate with the earlier studies, employing various neuroimagining techniques. This research signifies the translational potential of a comprehensive approach integrating ML, graph theory and rs-fMRI analysis in AD prediction, offering potential biomarker for more accurate diagnostics and early prediction of AD.

Prediction of Alzheimer's disease stages based on ResNet-Self-attention architecture with Bayesian optimization and best features selection

Alzheimer's disease (AD) is a neurodegenerative illness that impairs cognition, function, and behavior by causing irreversible damage to multiple brain areas, including the hippocampus. The suffering of the patients and their family members will be lessened with an early diagnosis of AD. The automatic diagnosis technique is widely required due to the shortage of medical experts and eases the burden of medical staff. The automatic artificial intelligence (AI)-based computerized method can help experts achieve better diagnosis accuracy and precision rates. This study proposes a new automated framework for AD stage prediction based on the ResNet-Self architecture and Fuzzy Entropy-controlled Path-Finding Algorithm (FEcPFA). A data augmentation technique has been utilized to resolve the dataset imbalance issue. In the next step, we proposed a new deep-learning model based on the self-attention module. A ResNet-50 architecture is modified and connected with a self-attention block for important information extraction. The hyperparameters were optimized using Bayesian optimization (BO) and then utilized to train the model, which was subsequently employed for feature extraction. The self-attention extracted features were optimized using the proposed FEcPFA. The best features were selected using FEcPFA and passed to the machine learning classifiers for the final classification. The experimental process utilized a publicly available MRI dataset and achieved an improved accuracy of 99.9%. The results were compared with state-of-the-art (SOTA) techniques, demonstrating the improvement of the proposed framework in terms of accuracy and time efficiency.

Multimodal classification of Alzheimer's disease and mild cognitive impairment using custom MKSCDDL kernel over CNN with transparent decision-making for explainable diagnosis

The study presents an innovative diagnostic framework that synergises Convolutional Neural Networks (CNNs) with a Multi-feature Kernel Supervised within-class-similar Discriminative Dictionary Learning (MKSCDDL). This integrative methodology is designed to facilitate the precise classification of individuals into categories of Alzheimer's Disease, Mild Cognitive Impairment (MCI), and Cognitively Normal (CN) statuses while also discerning the nuanced phases within the MCI spectrum. Our approach is distinguished by its robustness and interpretability, offering clinicians an exceptionally transparent tool for diagnosis and therapeutic strategy formulation. We use scandent decision trees to deal with the unpredictability and complexity of neuroimaging data. Considering that different people's brain scans are different, this enables the model to make more detailed individualised assessments and explains how the algorithm illuminates the specific neuroanatomical regions that are indicative of cognitive impairment. This explanation is beneficial for clinicians because it gives them concrete ideas for early intervention and targeted care. The empirical review of our model shows that it makes diagnoses with a level of accuracy that is unmatched, with a classification efficacy of 98.27%. This shows that the model is good at finding important parts of the brain that may be damaged by cognitive diseases.

Breaking barriers: a statistical and machine learning-based hybrid system for predicting dementia

Introduction: Dementia is a condition (a collection of related signs and symptoms) that causes a continuing deterioration in cognitive function, and millions of people are impacted by dementia every year as the world population continues to rise. Conventional approaches for determining dementia rely primarily on clinical examinations, analyzing medical records, and administering cognitive and neuropsychological testing. However, these methods are time-consuming and costly in terms of treatment. Therefore, this study aims to present a noninvasive method for the early prediction of dementia so that preventive steps should be taken to avoid dementia. Methods: We developed a hybrid diagnostic system based on statistical and machine learning (ML) methods that used patient electronic health records to predict dementia. The dataset used for this study was obtained from the Swedish National Study on Aging and Care (SNAC), with a sample size of 43040 and 75 features. The newly constructed diagnostic extracts a subset of useful features from the dataset through a statistical method (F-score). For the classification, we developed an ensemble voting classifier based on five different ML models: decision tree (DT), naive Bayes (NB), logistic regression (LR), support vector machines (SVM), and random forest (RF). To address the problem of ML model overfitting, we used a cross-validation approach to evaluate the performance of the proposed diagnostic system. Various assessment measures, such as accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curve, and Matthew's correlation coefficient (MCC), were used to thoroughly validate the devised diagnostic system's efficiency. Results: According to the experimental results, the proposed diagnostic method achieved the best accuracy of 98.25%, as well as sensitivity of 97.44%, specificity of 95.744%, and MCC of 0.7535. Discussion: The effectiveness of the proposed diagnostic approach is compared to various cutting-edge feature selection techniques and baseline ML models. From experimental results, it is evident that the proposed diagnostic system outperformed the prior feature selection strategies and baseline ML models regarding accuracy.

The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment

Alzheimer's disease (AD) is a well-known chronic neurodegenerative disorder that leads to the progressive death of brain cells, resulting in memory loss and the loss of other critical body functions. In March 2019, one of the major pharmaceutical companies and its partners announced that currently, there is no drug to cure AD, and all clinical trials of the new ones have been cancelled, leaving many people without hope. However, despite the clear message and startling reality, the research continued. Finally, in the last two years, the Food and Drug Administration (FDA) approved the first-ever medications to treat Alzheimer's, aducanumab and lecanemab. Despite researchers' support of this decision, there are serious concerns about their effectiveness and safety. The validation of aducanumab by the Centers for Medicare and Medicaid Services is still pending, and lecanemab was authorized without considering data from the phase III trials. Furthermore, numerous reports suggest that patients have died when undergoing extended treatment. While there is evidence that aducanumab and lecanemab may provide some relief to those suffering from AD, their impact remains a topic of ongoing research and debate within the medical community. The fact is that even though there are considerable efforts regarding pharmacological treatment, no definitive cure for AD has been found yet. Nevertheless, it is strongly believed that modern nanotechnology holds promising solutions and effective clinical strategies for the development of diagnostic tools and treatments for AD. This review summarizes the major hallmarks of AD, its etiological mechanisms, and challenges. It explores existing diagnostic and therapeutic methods and the potential of nanotechnology-based approaches for recognizing and monitoring patients at risk of irreversible neuronal degeneration. Overall, it provides a broad overview for those interested in the evolving areas of clinical neuroscience, AD, and related nanotechnology. With further research and development, nanotechnology-based approaches may offer new solutions and hope for millions of people affected by this devastating disease.

Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA

Biomarker-based differential diagnosis of the most common forms of dementia is becoming increasingly important. Machine learning (ML) may be able to address this challenge. The aim of this study was to develop and interpret a ML algorithm capable of differentiating Alzheimer's dementia, frontotemporal dementia, dementia with Lewy bodies and cognitively normal control subjects based on sociodemographic, clinical, and magnetic resonance imaging (MRI) variables. 506 subjects from 5 databases were included. MRI images were processed with FreeSurfer, LPA, and TRACULA to obtain brain volumes and thicknesses, white matter lesions and diffusion metrics. MRI metrics were used in conjunction with clinical and demographic data to perform differential diagnosis based on a Support Vector Machine model called MUQUBIA (Multimodal Quantification of Brain whIte matter biomArkers). Age, gender, Clinical Dementia Rating (CDR) Dementia Staging Instrument, and 19 imaging features formed the best set of discriminative features. The predictive model performed with an overall Area Under the Curve of 98%, high overall precision (88%), recall (88%), and F1 scores (88%) in the test group, and good Label Ranking Average Precision score (0.95) in a subset of neuropathologically assessed patients. The results of MUQUBIA were explained by the SHapley Additive exPlanations (SHAP) method. The MUQUBIA algorithm successfully classified various dementias with good performance using cost-effective clinical and MRI information, and with independent validation, has the potential to assist physicians in their clinical diagnosis.

Early-stage mapping of macromolecular content in APPNL-F mouse model of Alzheimer's disease using nuclear Overhauser effect MRI

Non-invasive methods of detecting early-stage Alzheimer's disease (AD) can provide valuable insight into disease pathology, improving the diagnosis and treatment of AD. Nuclear Overhauser enhancement (NOE) MRI is a technique that provides image contrast sensitive to lipid and protein content in the brain. These macromolecules have been shown to be altered in Alzheimer's pathology, with early disruptions in cell membrane integrity and signaling pathways leading to the buildup of amyloid-beta plaques and neurofibrillary tangles. We used template-based analyzes of NOE MRI data and the characteristic Z-spectrum, with parameters optimized for increase specificity to NOE, to detect changes in lipids and proteins in an AD mouse model that recapitulates features of human AD. We find changes in NOE contrast in the hippocampus, hypothalamus, entorhinal cortex, and fimbria, with these changes likely attributed to disruptions in the phospholipid bilayer of cell membranes in both gray and white matter regions. This study suggests that NOE MRI may be a useful tool for monitoring early-stage changes in lipid-mediated metabolism in AD and other disorders with high spatial resolution.

Detection of Alzheimer's disease onset using MRI and PET neuroimaging: longitudinal data analysis and machine learning

The scientists are dedicated to studying the detection of Alzheimer's disease onset to find a cure, or at the very least, medication that can slow the progression of the disease. This article explores the effectiveness of longitudinal data analysis, artificial intelligence, and machine learning approaches based on magnetic resonance imaging and positron emission tomography neuroimaging modalities for progression estimation and the detection of Alzheimer's disease onset. The significance of feature extraction in highly complex neuroimaging data, identification of vulnerable brain regions, and the determination of the threshold values for plaques, tangles, and neurodegeneration of these regions will extensively be evaluated. Developing automated methods to improve the aforementioned research areas would enable specialists to determine the progression of the disease and find the link between the biomarkers and more accurate detection of Alzheimer's disease onset.

Genetic algorithms based optimized hybrid deep learning model for explainable Alzheimer's prediction based on temporal multimodal cognitive data.. [DOI: 10.21203/rs.3.rs-3250006/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0]

Alzheimer's Disease (AD) is an irreversible neurodegenerative disease. Its early detection is crucial to stop disease progression at an early stage. Most deep learning (DL) literature focused on neuroimage analysis. However, there is no noticed effect of these studies in the real environment. Model's robustness, cost, and interpretability are considered the main reasons for these limitations. The medical intuition of physicians is to evaluate the clinical biomarkers of patients then test their neuroimages. Cognitive scores provide an medically acceptable and cost-effective alternative for the neuroimages to predict AD progression. Each score is calculated from a collection of sub-scores which provide a deeper insight about patient conditions. No study in the literature have explored the role of these multimodal time series sub-scores to predict AD progression. We propose a hybrid CNN-LSTM DL model for predicting AD progression based on the fusion of four longitudinal cognitive sub-scores modalities. Bayesian optimizer has been used to select the best DL architecture. A genetic algorithms based feature selection optimization step has been added to the pipeline to select the best features from extracted deep representations of CNN-LSTM. The SoftMax classifier has been replaced by a robust and optimized random forest classifier. Extensive experiments using the ADNI dataset investigated the role of each optimization step, and the proposed model achieved the best results compared to other DL and classical machine learning models. The resulting model is robust, but it is a black box and it is difficult to understand the logic behind its decisions. Trustworthy AI models must be robust and explainable. We used SHAP and LIME to provide explainability features for the proposed model. The resulting trustworthy model has a great potential to be used to provide decision support in the real environments.

Brain disease research based on functional magnetic resonance imaging data and machine learning: a review

Brain diseases, including neurodegenerative diseases and neuropsychiatric diseases, have long plagued the lives of the affected populations and caused a huge burden on public health. Functional magnetic resonance imaging (fMRI) is an excellent neuroimaging technology for measuring brain activity, which provides new insight for clinicians to help diagnose brain diseases. In recent years, machine learning methods have displayed superior performance in diagnosing brain diseases compared to conventional methods, attracting great attention from researchers. This paper reviews the representative research of machine learning methods in brain disease diagnosis based on fMRI data in the recent three years, focusing on the most frequent four active brain disease studies, including Alzheimer's disease/mild cognitive impairment, autism spectrum disorders, schizophrenia, and Parkinson's disease. We summarize these 55 articles from multiple perspectives, including the effect of the size of subjects, extracted features, feature selection methods, classification models, validation methods, and corresponding accuracies. Finally, we analyze these articles and introduce future research directions to provide neuroimaging scientists and researchers in the interdisciplinary fields of computing and medicine with new ideas for AI-aided brain disease diagnosis.

Hippocampal grading provides higher classification accuracy for those in the AD trajectory than hippocampal volume

Much research has focused on neurodegeneration in aging and Alzheimer's disease (AD). We developed Scoring by Nonlocal Image Patch Estimator (SNIPE), a non-local patch-based measure of anatomical similarity and hippocampal segmentation to measure hippocampal change. While SNIPE shows enhanced predictive power over hippocampal volume, it is unknown whether SNIPE is more strongly associated with group differences between normal controls (NC), early MCI (eMCI), late (lMCI), and AD than hippocampal volume. Alzheimer's Disease Neuroimaging Initiative older adults were included in the first analyses (N = 1666, 513 NCs, 269 eMCI, 556 lMCI, and 328 AD). Sub-analyses investigated amyloid positive individuals (N = 834; 179 NC, 148 eMCI, 298 lMCI, and 209 AD) to determine accuracy in those on the AD trajectory. We compared SNIPE grading, SNIPE volume, and Freesurfer volume as features in seven different machine learning techniques classifying participants into their correct cohort using 10-fold cross-validation. The best model was then validated in the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). SNIPE grading provided the highest classification accuracy for all classifications in both the full and amyloid positive sample. When classifying NC:AD, SNIPE grading provided an 89% accuracy (full sample) and 87% (amyloid positive sample). Freesurfer volume provided much lower accuracies of 65% (full sample) and 46% (amyloid positive sample). In the AIBL validation cohort, SNIPE grading provided a 90% classification accuracy for NC:AD. These findings suggest SNIPE grading provides increased classification accuracy over both SNIPE and Freesurfer volume. SNIPE grading offers promise to accurately identify people with and without AD.

Single-cell sequencing of entorhinal cortex reveals widespread disruption of neuropeptide networks in Alzheimer's disease

INTRODUCTION

Abnormalities of neuropeptides (NPs) that play important roles in modulating neuronal activities are commonly observed in Alzheimer's disease (AD). We hypothesize that NP network disruption is widespread in AD brains.

METHODS

Single-cell transcriptomic data from the entorhinal cortex (EC) were used to investigate the NP network disruption in AD. Bulk RNA-sequencing data generated from the temporal cortex by independent groups and machine learning were employed to identify key NPs involved in AD. The relationship between aging and AD-associated NP (ADNP) expression was studied using GTEx data.

RESULTS

The proportion of cells expressing NPs but not their receptors decreased significantly in AD. Neurons expressing higher level and greater diversity of NPs were disproportionately absent in AD. Increased age coincides with decreased ADNP expression in the hippocampus.

DISCUSSION

NP network disruption is widespread in AD EC. Neurons expressing more NPs may be selectively vulnerable to AD. Decreased expression of NPs participates in early AD pathogenesis. We predict that the NP network can be harnessed for treatment and/or early diagnosis of AD.

Eye movement changes as an indicator of mild cognitive impairment

Background

Early identification of patients at risk of dementia, alongside timely medical intervention, can prevent disease progression. Despite their potential clinical utility, the application of diagnostic tools, such as neuropsychological assessments and neuroimaging biomarkers, is hindered by their high cost and time-consuming administration, rendering them impractical for widespread implementation in the general population. We aimed to develop non-invasive and cost-effective classification models for predicting mild cognitive impairment (MCI) using eye movement (EM) data.

Methods

We collected eye-tracking (ET) data from 594 subjects, 428 cognitively normal controls, and 166 patients with MCI while they performed prosaccade/antisaccade and go/no-go tasks. Logistic regression (LR) was used to calculate the EM metrics' odds ratios (ORs). We then used machine learning models to construct classification models using EM metrics, demographic characteristics, and brief cognitive screening test scores. Model performance was evaluated based on the area under the receiver operating characteristic curve (AUROC).

Results

LR models revealed that several EM metrics are significantly associated with increased odds of MCI, with odds ratios ranging from 1.213 to 1.621. The AUROC scores for models utilizing demographic information and either EM metrics or MMSE were 0.752 and 0.767, respectively. Combining all features, including demographic, MMSE, and EM, notably resulted in the best-performing model, which achieved an AUROC of 0.840.

Conclusion

Changes in EM metrics linked with MCI are associated with attentional and executive function deficits. EM metrics combined with demographics and cognitive test scores enhance MCI prediction, making it a non-invasive, cost-effective method to identify early stages of cognitive decline.

Spatial-temporal data-augmentation-based functional brain network analysis for brain disorders identification

Introduction

Due to the lack of devices and the difficulty of gathering patients, the small sample size is one of the most challenging problems in functional brain network (FBN) analysis. Previous studies have attempted to solve this problem of sample limitation through data augmentation methods, such as sample transformation and noise addition. However, these methods ignore the unique spatial-temporal information of functional magnetic resonance imaging (fMRI) data, which is essential for FBN analysis.

Methods

To address this issue, we propose a spatial-temporal data-augmentation-based classification (STDAC) scheme that can fuse the spatial-temporal information, increase the samples, while improving the classification performance. Firstly, we propose a spatial augmentation module utilizing the spatial prior knowledge, which was ignored by previous augmentation methods. Secondly, we design a temporal augmentation module by random discontinuous sampling period, which can generate more samples than former approaches. Finally, a tensor fusion method is used to combine the features from the above two modules, which can make efficient use of spatial-temporal information of fMRI simultaneously. Besides, we apply our scheme to different types of classifiers to verify the generalization performance. To evaluate the effectiveness of our proposed scheme, we conduct extensive experiments on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and REST-meta-MDD Project (MDD) dataset.

Results

Experimental results show that the proposed scheme achieves superior classification accuracy (ADNI: 82.942%, MDD: 63.406%) and feature interpretation on the benchmark datasets.

Discussion

The proposed STDAC scheme, utilizing both spatial and temporal information, can generate more diverse samples than former augmentation methods for brain disorder classification and analysis.

Machine learning at the edge for AI-enabled multiplexed pathogen detection

Multiplexed detection of biomarkers in real-time is crucial for sensitive and accurate diagnosis at the point of use. This scenario poses tremendous challenges for detection and identification of signals of varying shape and quality at the edge of the signal-to-noise limit. Here, we demonstrate a robust target identification scheme that utilizes a Deep Neural Network (DNN) for multiplex detection of single particles and molecular biomarkers. The model combines fast wavelet particle detection with Short-Time Fourier Transform analysis, followed by DNN identification on an AI-specific edge device (Google Coral Dev board). The approach is validated using multi-spot optical excitation of Klebsiella Pneumoniae bacterial nucleic acids flowing through an optofluidic waveguide chip that produces fluorescence signals of varying amplitude, duration, and quality. Amplification-free 3× multiplexing in real-time is demonstrated with excellent specificity, sensitivity, and a classification accuracy of 99.8%. These results show that a minimalistic DNN design optimized for mobile devices provides a robust framework for accurate pathogen detection using compact, low-cost diagnostic devices.

Monte Carlo Ensemble Neural Network for the diagnosis of Alzheimer's disease

Convolutional neural networks (CNNs) have been increasingly used in the computer-aided diagnosis of Alzheimer's Disease (AD). This study takes the advantage of the 2D-slice CNN fast computation and ensemble approaches to develop a Monte Carlo Ensemble Neural Network (MCENN) by introducing Monte Carlo sampling and an ensemble neural network in the integration with ResNet50. Our goals are to improve the 2D-slice CNN performance and to design the MCENN model insensitive to image resolution. Unlike traditional ensemble approaches with multiple base learners, our MCENN model incorporates one neural network learner and generates a large number of possible classification decisions via Monte Carlo sampling of feature importance within the combined slices. This can overcome the main weakness of the lack of 3D brain anatomical information in 2D-slice CNNs and develop a neural network to learn the 3D relevance of the features across multiple slices. Brain images from Alzheimer's Disease Neuroimaging Initiative (ADNI, 7199 scans), the Open Access Series of Imaging Studies-3 (OASIS-3, 1992 scans), and a clinical sample (239 scans) are used to evaluate the performance of the MCENN model for the classification of cognitively normal (CN), patients with mild cognitive impairment (MCI) and AD. Our MCENN with a small number of slices and minimal image processing (rigid transformation, intensity normalization, skull stripping) achieves the AD classification accuracy of 90%, better than existing 2D-slice CNNs (accuracy: 63%∼84%) and 3D CNNs (accuracy: 74%∼88%). Furthermore, the MCENN is robust to be trained in the ADNI dataset and applied to the OASIS-3 dataset and the clinical sample. Our experiments show that the AD classification accuracy of the MCENN model is comparable when using high- and low-resolution brain images, suggesting the insensitivity of the MCENN to image resolution. Hence, the MCENN does not require high-resolution 3D brain structural images and comprehensive image processing, which supports its potential use in a clinical setting.

A transfer learning approach for multiclass classification of Alzheimer's disease using MRI images

Alzheimer's is an acute degenerative disease affecting the elderly population all over the world. The detection of disease at an early stage in the absence of a large-scale annotated dataset is crucial to the clinical treatment for the prevention and early detection of Alzheimer's disease (AD). In this study, we propose a transfer learning base approach to classify various stages of AD. The proposed model can distinguish between normal control (NC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and AD. In this regard, we apply tissue segmentation to extract the gray matter from the MRI scans obtained from the Alzheimer's Disease National Initiative (ADNI) database. We utilize this gray matter to tune the pre-trained VGG architecture while freezing the features of the ImageNet database. It is achieved through the addition of a layer with step-wise freezing of the existing blocks in the network. It not only assists transfer learning but also contributes to learning new features efficiently. Extensive experiments are conducted and results demonstrate the superiority of the proposed approach.

DAD-Net: Classification of Alzheimer's Disease Using ADASYN Oversampling Technique and Optimized Neural Network

Alzheimer's Disease (AD) is a neurological brain disorder that causes dementia and neurological dysfunction, affecting memory, behavior, and cognition. Deep Learning (DL), a kind of Artificial Intelligence (AI), has paved the way for new AD detection and automation methods. The DL model's prediction accuracy depends on the dataset's size. The DL models lose their accuracy when the dataset has an imbalanced class problem. This study aims to use the deep Convolutional Neural Network (CNN) to develop a reliable and efficient method for identifying Alzheimer's disease using MRI. In this study, we offer a new CNN architecture for diagnosing Alzheimer's disease with a modest number of parameters, making it perfect for training a smaller dataset. This proposed model correctly separates the early stages of Alzheimer's disease and displays class activation patterns on the brain as a heat map. The proposed Detection of Alzheimer's Disease Network (DAD-Net) is developed from scratch to correctly classify the phases of Alzheimer's disease while reducing parameters and computation costs. The Kaggle MRI image dataset has a severe problem with class imbalance. Therefore, we used a synthetic oversampling technique to distribute the image throughout the classes and avoid the problem. Precision, recall, F1-score, Area Under the Curve (AUC), and loss are all used to compare the proposed DAD-Net against DEMENET and CNN Model. For accuracy, AUC, F1-score, precision, and recall, the DAD-Net achieved the following values for evaluation metrics: 99.22%, 99.91%, 99.19%, 99.30%, and 99.14%, respectively. The presented DAD-Net outperforms other state-of-the-art models in all evaluation metrics, according to the simulation results.

Altered Microcirculation in Alzheimer's Disease Assessed by Machine Learning Applied to Functional Thermal Imaging Data

Alzheimer's disease (AD) is characterized by progressive memory failures accompanied by microcirculation alterations. Particularly, impaired endothelial microvascular responsiveness and altered flow motion patterns have been observed in AD patients. Of note, the endothelium influences the vascular tone and also the small superficial blood vessels, which can be evaluated through infrared thermography (IRT). The advantage of IRT with respect to other techniques relies on its contactless features and its capability to preserve spatial information of the peripheral microcirculation. The aim of the study is to investigate peripheral microcirculation impairments in AD patients with respect to age-matched healthy controls (HCs) at resting state, through IRT and machine learning (ML) approaches. Particularly, several classifiers were tested, employing as regressors the power of the nose tip temperature time course in different physiological frequency bands. Among the ML classifiers tested, the Decision Tree Classifier (DTC) delivered the best cross-validated accuracy (accuracy = 82%) when discriminating between AD and HCs. The results further demonstrate the alteration of microvascular patterns in AD in the early stages of the pathology, and the capability of IRT to assess vascular impairments. These findings could be exploited in clinical practice, fostering the employment of IRT as a support for the early diagnosis of AD.

A dominant set-informed interpretable fuzzy system for automated diagnosis of dementia

Dementia is an incurable neurodegenerative disease primarily affecting the older population, for which the World Health Organisation has set to promoting early diagnosis and timely management as one of the primary goals for dementia care. While a range of popular machine learning algorithms and their variants have been applied for dementia diagnosis, fuzzy systems, which have been known effective in dealing with uncertainty and offer to explicitly reason how a diagnosis can be inferred, sporadically appear in recent literature. Given the advantages of a fuzzy rule-based model, which could potentially result in a clinical decision support system that offers understandable rules and a transparent inference process to support dementia diagnosis, this paper proposes a novel fuzzy inference system by adapting the concept of dominant sets that arise from the study of graph theory. A peeling-off strategy is used to iteratively extract from the constructed edge-weighted graph a collection of dominant sets. Each dominant set is further converted into a parameterized fuzzy rule, which is finally optimized in a supervised adaptive network-based fuzzy inference framework. An illustrative example is provided that demonstrates the interpretable rules and the transparent reasoning process of reaching a decision. Further systematic experiments conducted on data from the Open Access Series of Imaging Studies (OASIS) repository, also validate its superior performance over alternative methods.

Bayesian Depth-Wise Convolutional Neural Network Design for Brain Tumor MRI Classification

In recent years, deep learning has been applied to many medical imaging fields, including medical image processing, bioinformatics, medical image classification, segmentation, and prediction tasks. Computer-aided detection systems have been widely adopted in brain tumor classification, prediction, detection, diagnosis, and segmentation tasks. This work proposes a novel model that combines the Bayesian algorithm with depth-wise separable convolutions for accurate classification and predictions of brain tumors. We combine Bayesian modeling learning and Convolutional Neural Network learning methods for accurate prediction results to provide the radiologists the means to classify the Magnetic Resonance Imaging (MRI) images rapidly. After thorough experimental analysis, our proposed model outperforms other state-of-the-art models in terms of validation accuracy, training accuracy, F1-score, recall, and precision. Our model obtained high performances of 99.03% training accuracy and 94.32% validation accuracy, F1-score, precision, and recall values of 0.94, 0.95, and 0.94, respectively. To the best of our knowledge, the proposed work is the first neural network model that combines the hybrid effect of depth-wise separable convolutions with the Bayesian algorithm using encoders.

Supervised Machine Learning Empowered Multifactorial Genetic Inheritance Disorder Prediction

Fatal diseases like cancer, dementia, and diabetes are very dangerous. This leads to fear of death if these are not diagnosed at early stages. Computer science uses biomedical studies to diagnose cancer, dementia, and diabetes. With the advancement of machine learning, there are various techniques which are accessible to predict and prognosis these diseases based on different datasets. These datasets varied (image datasets and CSV datasets) around the world. So, there is a need for some machine learning classifiers to predict cancer, dementia, and diabetes in a human. In this paper, we used a multifactorial genetic inheritance disorder dataset to predict cancer, dementia, and diabetes. Several studies used different machine learning classifiers to predict cancer, dementia, and diabetes separately with the help of different types of datasets. So, in this paper, multiclass classification proposed methodology used support vector machine (SVM) and K-nearest neighbor (KNN) machine learning techniques to predict three diseases and compared these techniques based on accuracy. Simulation results have shown that the proposed model of SVM and KNN for prediction of dementia, cancer, and diabetes from multifactorial genetic inheritance disorder achieved 92.8% and 92.5%, 92.8% and 91.2% accuracy during training and testing, respectively. So, it is observed that proposed SVM-based dementia, cancer, and diabetes from multifactorial genetic inheritance disorder prediction (MGIDP) give attractive results as compared with the proposed model of KNN. The application of the proposed model helps to prognosis and prediction of cancer, dementia, and diabetes before time and plays a vital role to minimize the death ratio around the world.

A Novel Key Features Screening Method Based on Extreme Learning Machine for Alzheimer's Disease Study

The Extreme Learning Machine (ELM) is a simple and efficient Single Hidden Layer Feedforward Neural Network(SLFN) algorithm. In recent years, it has been gradually used in the study of Alzheimer's disease (AD). When using ELM to diagnose AD based on high-dimensional features, there are often some features that have no positive impact on the diagnosis, while others have a significant impact on the diagnosis. In this paper, a novel Key Features Screening Method based on Extreme Learning Machine (KFS-ELM) is proposed. It can screen for key features that are relevant to the classification (diagnosis). It can also assign weights to key features based on their importance. We designed an experiment to screen for key features of AD. A total of 920 key functional connections screened from 4005 functional connections. Their weights were also obtained. The results of the experiment showed that: (1) Using all (4,005) features to diagnose AD, the accuracy is 95.33%. Using 920 key features to diagnose AD, the accuracy is 99.20%. The 3,085 (4,005 - 920) features that were screened out had a negative effect on the diagnosis of AD. This indicates the KFS-ELM is effective in screening key features. (2) The higher the weight of the key features and the smaller their number, the greater their impact on AD diagnosis. This indicates that the KFS-ELM is rational in assigning weights to the key features for their importance. Therefore, KFS-ELM can be used as a tool for studying features and also for improving classification accuracy.

EEG-Based Alzheimer's Disease Recognition Using Robust-PCA and LSTM Recurrent Neural Network

The use of electroencephalography (EEG) has recently grown as a means to diagnose neurodegenerative pathologies such as Alzheimer's disease (AD). AD recognition can benefit from machine learning methods that, compared with traditional manual diagnosis methods, have higher reliability and improved recognition accuracy, being able to manage large amounts of data. Nevertheless, machine learning methods may exhibit lower accuracies when faced with incomplete, corrupted, or otherwise missing data, so it is important do develop robust pre-processing techniques do deal with incomplete data. The aim of this paper is to develop an automatic classification method that can still work well with EEG data affected by artifacts, as can arise during the collection with, e.g., a wireless system that can lose packets. We show that a recurrent neural network (RNN) can operate successfully even in the case of significantly corrupted data, when it is pre-filtered by the robust principal component analysis (RPCA) algorithm. RPCA was selected because of its stated ability to remove outliers from the signal. To demonstrate this idea, we first develop an RNN which operates on EEG data, properly processed through traditional PCA; then, we use corrupted data as input and process them with RPCA to filter outlier components, showing that even with data corruption causing up to 20% erasures, the RPCA was able to increase the detection accuracy by about 5% with respect to the baseline PCA.

Regional Brain Fusion: Graph Convolutional Network for Alzheimer's Disease Prediction and Analysis

Alzheimer's disease (AD) has raised extensive concern in healthcare and academia as one of the most prevalent health threats to the elderly. Due to the irreversible nature of AD, early and accurate diagnoses are significant for effective prevention and treatment. However, diverse clinical symptoms and limited neuroimaging accuracy make diagnoses challenging. In this article, we built a brain network for each subject, which assembles several commonly used neuroimaging data simply and reasonably, including structural magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), and amyloid positron emission tomography (PET). Based on some existing research results, we applied statistical methods to analyze (i) the distinct affinity of AD burden on each brain region, (ii) the topological lateralization between left and right hemispheric sub-networks, and (iii) the asymmetry of the AD attacks on the left and right hemispheres. In the light of advances in graph convolutional networks for graph classifications and summarized characteristics of brain networks and AD pathologies, we proposed a regional brain fusion-graph convolutional network (RBF-GCN), which is constructed with an RBF framework mainly, including three sub-modules, namely, hemispheric network generation module, multichannel GCN module, and feature fusion module. In the multichannel GCN module, the improved GCN by our proposed adaptive native node attribute (ANNA) unit embeds within each channel independently. We not only fully verified the effectiveness of the RBF framework and ANNA unit but also achieved competitive results in multiple sets of AD stages' classification tasks using hundreds of experiments over the ADNI clinical dataset.

Alzheimer's Disease Diagnosis With Brain Structural MRI Using Multiview-Slice Attention and 3D Convolution Neural Network

Numerous artificial intelligence (AI) based approaches have been proposed for automatic Alzheimer's disease (AD) prediction with brain structural magnetic resonance imaging (sMRI). Previous studies extract features from the whole brain or individual slices separately, ignoring the properties of multi-view slices and feature complementarity. For this reason, we present a novel AD diagnosis model based on the multiview-slice attention and 3D convolution neural network (3D-CNN). Specifically, we begin by extracting the local slice-level characteristic in various dimensions using multiple sub-networks. Then we proposed a slice-level attention mechanism to emphasize specific 2D-slices to exclude the redundancy features. After that, a 3D-CNN was employed to capture the global subject-level structural changes. Finally, all these 2D and 3D features were fused to obtain more discriminative representations. We conduct the experiments on 1,451 subjects from ADNI-1 and ADNI-2 datasets. Experimental results showed the superiority of our model over the state-of-the-art approaches regarding dementia classification. Specifically, our model achieves accuracy values of 91.1 and 80.1% on ADNI-1 for AD diagnosis and mild cognitive impairment (MCI) convention prediction, respectively.

Enhanced Fuzzy Elephant Herding Optimization-Based OTSU Segmentation and Deep Learning for Alzheimer’s Disease Diagnosis

Several neurological illnesses and diseased sites have been studied, along with the anatomical framework of the brain, using structural MRI (sMRI). It is critical to diagnose Alzheimer’s disease (AD) patients in a timely manner to implement preventative treatments. The segmentation of brain anatomy and categorization of AD have received increased attention since they can deliver good findings spanning a vast range of information. The first research gap considered in this work is the real-time efficiency of OTSU segmentation, which is not high, despite its simplicity and good accuracy. A second issue is that feature extraction could be automated by implementing deep learning techniques. To improve picture segmentation’s real-timeliness, enhanced fuzzy elephant herding optimization (EFEHO) was used for OTSU segmentation, and named EFEHO-OTSU. The main contribution of this work is twofold. One is utilizing EFEHO in the recommended technique to seek the optimal segmentation threshold for the OTSU method. Second, dual attention multi-instance deep learning network (DA-MIDL) is recommended for the timely diagnosis of AD and its prodromal phase, mild cognitive impairment (MCI). Tests show that this technique converges faster and takes less time than the classic OTSU approach without reducing segmentation performance. This study develops a valuable tool for quick picture segmentation with good real-time efficiency. Compared to numerous conventional techniques, the suggested study attains improved categorization performance regarding accuracy and transferability.

Machine Learning Framework for the Prediction of Alzheimer’s Disease Using Gene Expression Data Based on Efficient Gene Selection

In recent years, much research has focused on using machine learning (ML) for disease prediction based on gene expression (GE) data. However, many diseases have received considerable attention, whereas some, including Alzheimer’s disease (AD), have not, perhaps due to data shortage. The present work is intended to fill this gap by introducing a symmetric framework to predict AD from GE data, with the aim to produce the most accurate prediction using the smallest number of genes. The framework works in four stages after it receives a training dataset: pre-processing, gene selection (GS), classification, and AD prediction. The symmetry of the model is manifested in all of its stages. In the pre-processing stage gene columns in the training dataset are pre-processed identically. In the GS stage, the same user-defined filter metrics are invoked on every gene individually, and so are the same user-defined wrapper metrics. In the classification stage, a number of user-defined ML models are applied identically using the minimal set of genes selected in the preceding stage. The core of the proposed framework is a meticulous GS algorithm which we have designed to nominate eight subsets of the original set of genes provided in the training dataset. Exploring the eight subsets, the algorithm selects the best one to describe AD, and also the best ML model to predict the disease using this subset. For credible results, the framework calculates performance metrics using repeated stratified k-fold cross validation. To evaluate the framework, we used an AD dataset of 1157 cases and 39,280 genes, obtained by combining a number of smaller public datasets. The cases were split in two partitions, 1000 for training/testing, using 10-fold CV repeated 30 times, and 157 for validation. From the testing/training phase, the framework identified only 1058 genes to be the most relevant and the support vector machine (SVM) model to be the most accurate with these genes. In the final validation, we used the 157 cases that were never seen by the SVM classifier. For credible performance evaluation, we evaluated the classifier via six metrics, for which we obtained impressive values. Specifically, we obtained 0.97, 0.97, 0.98, 0.945, 0.972, and 0.975 for the sensitivity (recall), specificity, precision, kappa index, AUC, and accuracy, respectively.

Pathogeny Detection for Mild Cognitive Impairment via Weighted Evolutionary Random Forest with Brain Imaging and Genetic Data

Medical imaging technology and gene sequencing technology have long been widely used to analyze the pathogenesis and make precise diagnoses of mild cognitive impairment (MCI). However, few studies involve the fusion of radiomics data with genomics data to make full use of the complementarity between different omics to detect pathogenic factors of MCI. This paper performs multimodal fusion analysis based on functional magnetic resonance imaging (fMRI) data and single nucleotide polymorphism (SNP) data of MCI patients. In specific, first, using correlation analysis methods on sequence information of regions of interests (ROIs) and digitalized gene sequences, the fusion features of samples are constructed. Then, introducing weighted evolution strategy into ensemble learning, a novel weighted evolutionary random forest (WERF) model is built to eliminate the inefficient features. Consequently, with the help of WERF, an overall multimodal data analysis framework is established to effectively identify MCI patients and extract pathogenic factors. Based on the data of MCI patients from the ADNI database and compared with some existing popular methods, the superiority in performance of the framework is verified. Our study has great potential to be an effective tool for pathogenic factors detection of MCI.

Multi-resolution 3D-HOG feature learning method for Alzheimer's Disease diagnosis

BACKGROUND AND OBJECTIVE

Alzheimer's Disease (AD) is a progressive irreversible neurodegeneration disease and thus timely identification is critical to delay its progression.

METHODS

In this work, we focus on the traditional branch to design discriminative feature extraction and selection strategies to achieve explainable AD identification. Specifically, a spatial pyramid based three-dimensional histogram of oriented gradient (3D-HOG) feature learning method is proposed. Both global and local texture changes are included in spatial pyramid 3D-HOG (SPHOG) features for comprehensive analysis. Then a modified wrapper-based feature selection algorithm is introduced to select the discriminative features for AD identification while reduce feature dimensions.

RESULTS

Discriminative SPHOG histograms with various resolutions are selected, which can represent the atrophy characteristics of cerebral cortex with promising performance. As subareas corresponding to selected histograms are consistent with clinical experience, explanatory is emphasized and illustrated with Hippocampus.

CONCLUSION

Experimental results illustrate the effectiveness of the proposed method on feature learning based on samples obtained from common dataset and a clinical dataset. The proposed method will be useful for further medical analysis as its explanatory on other region-of-interests (ROIs) of the brain for early diagnosis of AD.

Machine Learning Approaches to Analyze MALDI-TOF Mass Spectrometry Protein Profiles

Machine learning is being employed for the development of diagnostic methods for several diseases, but prognostic techniques are still poorly explored. The development of such approaches is essential to assist healthcare workers to ensure the most appropriate treatment for patients. In this chapter, we demonstrate a detailed protocol for the application of machine learning to MALDI-TOF MS spectra of COVID-19-infected plasma samples for risk classification and biomarker identification.

Prediction of neuro-degenerative disorders using sunflower optimisation algorithm and Kernel extreme learning machine: A case-study with Parkinson's and Alzheimer's disease

Parkinson's and Alzheimer's Disease are believed to be most prevalent and common in older people. Several data-mining approaches are employed on the neuro-degenerative data in predicting the disease. A novel method has been built and developed to diagnose Alzheimer's (AD) and Parkinson's (PD) in early stages, which includes image acquisition, pre-processing, feature extraction and selection, followed by classification. The challenge lies in selecting the optimal feature subset for classification. In this work, the Sunflower Optimisation Algorithm (SFO) is employed to select the optimal feature set, which is then fed to the Kernel Extreme Learning Machine (KELM) for classification. The method is tested on the Alzheimer's Disease Neuroimaging Initiative (ADNI) and local dataset for AD, the University of California, Irvine (UCI) machine learning repository and the Istanbul dataset for PD. Experimental outcomes have demonstrated a high accuracy level in both AD and PD diagnosis. For AD diagnosis, the highest classification rate is obtained for the AD versus NC classification using the ADNI dataset (99.32%) and local dataset (98.65%). For PD diagnosis, the highest accuracy of 99.52% and 99.45% is achieved on the UCI and Istanbul datasets, respectively. To show the robustness of the method, the method is compared with other similar methods of feature selection and classification with 10-fold cross-validation (CV) and with unseen data. The method proposed has an excellent prospect, bringing greater convenience to clinicians in making a better solid decision in clinical diagnosis of neuro-degenerative diseases.

Improving the Classification of Alzheimer's Disease Using Hybrid Gene Selection Pipeline and Deep Learning

Alzheimer’s is a progressive, irreversible, neurodegenerative brain disease. Even with prominent symptoms, it takes years to notice, decode, and reveal Alzheimer’s. However, advancements in technologies, such as imaging techniques, help in early diagnosis. Still, sometimes the results are inaccurate, which delays the treatment. Thus, the research in recent times focused on identifying the molecular biomarkers that differentiate the genotype and phenotype characteristics. However, the gene expression dataset’s generated features are huge, 1,000 or even more than 10,000. To overcome such a curse of dimensionality, feature selection techniques are introduced. We designed a gene selection pipeline combining a filter, wrapper, and unsupervised method to select the relevant genes. We combined the minimum Redundancy and maximum Relevance (mRmR), Wrapper-based Particle Swarm Optimization (WPSO), and Auto encoder to select the relevant features. We used the GSE5281 Alzheimer’s dataset from the Gene Expression Omnibus We implemented an Improved Deep Belief Network (IDBN) with simple stopping criteria after choosing the relevant genes. We used a Bayesian Optimization technique to tune the hyperparameters in the Improved Deep Belief Network. The tabulated results show that the proposed pipeline shows promising results.

Discovery of Genetic Biomarkers for Alzheimer's Disease Using Adaptive Convolutional Neural Networks Ensemble and Genome-Wide Association Studies

OBJECTIVE

To identify candidate neuroimaging and genetic biomarkers for Alzheimer's disease (AD) and other brain disorders, especially for little-investigated brain diseases, we advocate a data-driven approach which incorporates an adaptive classifier ensemble model acquired by integrating Convolutional Neural Network (CNN) and Ensemble Learning (EL) with Genetic Algorithm (GA), i.e., the CNN-EL-GA method, into Genome-Wide Association Studies (GWAS).

METHODS

Above all, a large number of CNN models as base classifiers were trained using coronal, sagittal, or transverse magnetic resonance imaging slices, respectively, and the CNN models with strong discriminability were then selected to build a single classifier ensemble with the GA for classifying AD, with the help of the CNN-EL-GA method. While the acquired classifier ensemble exhibited the highest generalization capability, the points of intersection were determined with the most discriminative coronal, sagittal, and transverse slices. Finally, we conducted GWAS on the genotype data and the phenotypes, i.e., the gray matter volumes of the top ten most discriminative brain regions, which contained the ten most points of intersection.

RESULTS

Six genes of PCDH11X/Y, TPTE2, LOC107985902, MUC16 and LINC01621 as well as Single-Nucleotide Polymorphisms, e.g., rs36088804, rs34640393, rs2451078, rs10496214, rs17016520, rs2591597, rs9352767 and rs5941380, were identified.

CONCLUSION

This approach overcomes the limitations associated with the impact of subjective factors and dependence on prior knowledge while adaptively achieving more robust and effective candidate biomarkers in a data-driven way.

SIGNIFICANCE

The approach is promising to facilitate discovering effective candidate genetic biomarkers for brain disorders, as well as to help improve the effectiveness of identified candidate neuroimaging biomarkers for brain diseases.

Deep learning assisted cognitive diagnosis for the D-Riska application

In this article, we expose a system developed that extends the Acquired Brain Injury (ABI) diagnostic application known as D-Riska with an artificial intelligence module that supports the diagnosis of ABI enabling therapists to evaluate patients in an assisted way. The application is in charge of collecting the data of the diagnostic tests of the patients, and due to a multi-class Convolutional Neural Network classifier (CNN), it is capable of making predictions that facilitate the diagnosis and the final score obtained in the test by the patient. To find out the best solution to this problem, different classifiers are used to compare the performance of the proposed model based on various classification metrics. The proposed CNN classifier makes predictions with 93 % of Accuracy, 94 % of Precision, 91 %, of Recall and 92% of F1-Score.

Transfer Learning for Alzheimer's Disease through Neuroimaging Biomarkers: A Systematic Review

Alzheimer's disease (AD) is a remarkable challenge for healthcare in the 21st century. Since 2017, deep learning models with transfer learning approaches have been gaining recognition in AD detection, and progression prediction by using neuroimaging biomarkers. This paper presents a systematic review of the current state of early AD detection by using deep learning models with transfer learning and neuroimaging biomarkers. Five databases were used and the results before screening report 215 studies published between 2010 and 2020. After screening, 13 studies met the inclusion criteria. We noted that the maximum accuracy achieved to date for AD classification is 98.20% by using the combination of 3D convolutional networks and local transfer learning, and that for the prognostic prediction of AD is 87.78% by using pre-trained 3D convolutional network-based architectures. The results show that transfer learning helps researchers in developing a more accurate system for the early diagnosis of AD. However, there is a need to consider some points in future research, such as improving the accuracy of the prognostic prediction of AD, exploring additional biomarkers such as tau-PET and amyloid-PET to understand highly discriminative feature representation to separate similar brain patterns, managing the size of the datasets due to the limited availability.

MRI Deep Learning-Based Solution for Alzheimer's Disease Prediction

BACKGROUND

Alzheimer's is a degenerative dementing disorder that starts with a mild memory impairment and progresses to a total loss of mental and physical faculties. The sooner the diagnosis is made, the better for the patient, as preventive actions and treatment can be started. Although tests such as the Mini-Mental State Tests Examination are usually used for early identification, diagnosis relies on magnetic resonance imaging (MRI) brain analysis.

METHODS

Public initiatives such as the OASIS (Open Access Series of Imaging Studies) collection provide neuroimaging datasets openly available for research purposes. In this work, a new method based on deep learning and image processing techniques for MRI-based Alzheimer's diagnosis is proposed and compared with previous literature works.

RESULTS

Our method achieves a balance accuracy (BAC) up to 0.93 for image-based automated diagnosis of the disease, and a BAC of 0.88 for the establishment of the disease stage (healthy tissue, very mild and severe stage).

CONCLUSIONS

Results obtained surpassed the state-of-the-art proposals using the OASIS collection. This demonstrates that deep learning-based strategies are an effective tool for building a robust solution for Alzheimer's-assisted diagnosis based on MRI data.

Relevance of Complaint Severity in Predicting the Progression of Subjective Cognitive Decline and Mild Cognitive Impairment: A Machine Learning Approach

BACKGROUND

The presence of subjective cognitive complaints (SCCs) is a core criterion for diagnosis of subjective cognitive decline (SCD); however, no standard procedure for distinguishing normative and non-normative SCCs has yet been established.

OBJECTIVE

To determine whether differentiation of participants with SCD according to SCC severity improves the validity of the prediction of progression in SCD and MCI and to explore validity metrics for two extreme thresholds of the distribution in scores in a questionnaire on SCCs.

METHODS

Two hundred and fifty-three older adults with SCCs participating in the Compostela Aging Study (CompAS) were classified as MCI or SCD at baseline. The participants underwent two follow-up assessments and were classified as cognitively stable or worsened. Severity of SCCs (low and high) in SCD was established by using two different percentiles of the questionnaire score distribution as cut-off points. The validity of these cut-off points for predicting progression using socio-demographic, health, and neuropsychological variables was tested by machine learning (ML) analysis.

RESULTS

Severity of SCCs in SCD established considering the 5th percentile as a cut-off point proved to be the best metric for predicting progression. The variables with the main role in conforming the predictive algorithm were those related to memory, cognitive reserve, general health, and the stability of diagnosis over time.

CONCLUSION

Moderate to high complainers showed an increased probability of progression in cognitive decline, suggesting the clinical relevance of standard procedures to determine SCC severity. Our findings highlight the important role of the multimodal ML approach in predicting progression.

Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease

A growing body of evidence currently proposes that deep learning approaches can serve as an essential cornerstone for the diagnosis and prediction of Alzheimer's disease (AD). In light of the latest advancements in neuroimaging and genomics, numerous deep learning models are being exploited to distinguish AD from normal controls and/or to distinguish AD from mild cognitive impairment in recent research studies. In this review, we focus on the latest developments for AD prediction using deep learning techniques in cooperation with the principles of neuroimaging and genomics. First, we narrate various investigations that make use of deep learning algorithms to establish AD prediction using genomics or neuroimaging data. Particularly, we delineate relevant integrative neuroimaging genomics investigations that leverage deep learning methods to forecast AD on the basis of incorporating both neuroimaging and genomics data. Moreover, we outline the limitations as regards to the recent AD investigations of deep learning with neuroimaging and genomics. Finally, we depict a discussion of challenges and directions for future research. The main novelty of this work is that we summarize the major points of these investigations and scrutinize the similarities and differences among these investigations.